OncXerna Therapeutics Announces New Biomarker Data from Retrospective Analysis of Results from Phase 1b Ovarian Cancer Trial of Navicixizumab Plus Paclitaxel at the ESGO 2021 Congress
62% vs. 25% overall response rates with navicixizumab plus paclitaxel in biomarker positive vs. biomarker…
Airwheel Introduces AI-Driven Rideable Smart Cabin Suitcase Solutions for the Next Generation of Global Travel
Formerra and Evonik Expand Distribution Partnership for Healthcare Grades
Casa Minerals Inc. Announces Closing of First Tranche of Private Placement
Hans Vestberg, Former Verizon Chairman and CEO, Joins Digipower X as Senior Advisor
Bioxytran and University of Minnesota Launch Sponsored Research Collaboration to Advance Novel Carbohydrate-Based Therapeutics